Cornea

Assessing two devices in a real-world setting

Investigators from Bergen, Norway, and Cleveland, Ohio, collaborated on the predictive model

Research indicates suppressive valacyclovir could help patients avoid keratitis and iritis flare-ups

Corneal confocal microscopy, semaglutide therapy offer treatment options

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers

A study led by researchers at the University of Birmingham finds AI-powered models can match ophthalmologists in diagnosing infectious keratitis, offering promise for global eye care improvements.

John D. Sheppard, MD, MMSc, FACS, spoke with the Eye Care Network to provide some insight on post hoc analysis of the ESSENCE 1 trial dor dry eye disease.

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

Farhad Hafezi, FARVO, MD, PhD, and colleagues reported on results achieved with phototherapeutic keratectomy-assisted, customised, epi-on corneal crosslinking

Dry eye increases susceptibility to psychiatric disorders and chronic pain syndromes, investigators reported at the 2024 AAO meeting

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive tolerability and safety profiles through 12 months, supporting an anticipated NDA submission by the end of 2024.

A Norwegian study demonstrates that transplant rates continue to drop over time

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease

Current and future options for Fuchs endothelial corneal dystrophy

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

Neltependocel has received both regulatory and reimbursement approval in Japan

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

TEPEZZA is the first and only medicine approved in Japan to treat active TED.

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias.

The new standard: Stabilizing keratoconus and improving vision.

Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.

Laura M. Periman, MD, shares her passion for dry eye disease, discussing her discovery of the Alpenglow Sign in Demodex blepharitis and her insights on research and education for clinicians. Periman will join the EyeCon 2024 faculty as Honorary Chair.

Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.”

Michael Goldstein, MD, discusses 12-month safety and efficacy trial data of human corneal endothelial cell therapy, presented at the 2024 ESCRS Congress